StemSmart™ MSC Therapy Revives Hope in Renal Transplant Patients

• 8 of 10 patients with refractory acute renal rejection retained their kidney after StemSmart™ MSC treatment
• Phase 1 study in 12 deceased-donor kidney recipients showed StemSmart™ MSC infusions were safe and well tolerated
• Evidence suggests StemSmart™ MSC may reduce delayed graft function and improve long-term kidney graft outcomes
• Therapy’s anti-inflammatory and immunomodulatory effects key to controlling rejection and ischemia-reperfusion injury